(Q37183451)

18 August 2017

1 reference

title

Immunotherapy for renal cell cancer in the era of targeted therapy (English)

1 reference

18 August 2017

1 reference

Chris Coppin

1

1 reference

18 August 2017

1 June 2008

1 reference

Expert Review of Anticancer Therapy

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

6

1 reference

18 August 2017

907-919

1 reference

Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Renal cell cancer: is immunotherapy dead?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Immunotherapy of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Current insights in renal cell cancer pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

The Heidelberg classification of renal cell tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Response of intracranial metastases to erlotinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Sunitinib efficacy against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Forecasting the cytokine storm following systemic interleukin (IL)-2 administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

The impact of interleukin-2 on survival in renal cancer: a multivariate analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Nephrectomy for metastatic renal-cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Lymphocyte therapy of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Adjuvant therapy for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (D

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Gains in life expectancy from medical interventions--standardizing data on outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Funding patient-reported outcomes in cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Prognostic markers in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Advancing cancer biotherapy with proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Dendritic cell-tumor fusion vaccines for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

DNA vaccines for cancer too.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Vaccines in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Stat3 as a potential target for cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Immune suppression in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.907

Immunotherapy for advanced renal cell cancer.

21 January 2018

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425

Identifiers

DOI

10.1586/14737140.8.6.907

1 reference

18 August 2017

1 reference

PubMed ID

18533800